BioPharmSignal logoBioPharmSignal

Company Profile

bioAffinity Technologies, Inc. Stock Price, News & Catalysts

Ticker:
BIAF
Exchange:
NASDAQ
Sector:
MedTech
Location:
United States

Stock performance

0.39 USD (-2.51%)

Close

Last updated: August 17, 2026

7.62M USD

Market cap

Why the stock is moving

The latest monitored company update is “bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung.” The corresponding closing-price reaction is not yet available.

Company overview

Noninvasive Lung Diagnostics

bioAffinity Technologies develops noninvasive tests for the early detection and characterization of lung disease. Its approach uses flow-cytometry and artificial-intelligence analysis of cells collected from sputum samples.

CyPath Lung

CyPath Lung is a laboratory-developed test intended to help assess patients at elevated risk of lung cancer, including those with indeterminate imaging findings. It is positioned between imaging surveillance and invasive diagnostic procedures. The company is also exploring applications of its cellular-analysis platform in asthma and chronic obstructive pulmonary disease, including potential companion-diagnostic uses.

Future catalysts

    Recent news

    1. 01

      bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung

    2. 02

      bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

    3. 03

      bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

    4. 04

      bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

    5. 05

      bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung

    Similar stocks

    Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

    BJDX

    Bluejay Diagnostics

    TTOO

    T2 Biosystems

    FLGT

    Fulgent Genetics, Inc.

    PRPO

    Precipio Diagnostics

    ANPC

    AnPac Bio-Medical Science

    EXAS

    Exact Sciences

    VRAX

    Virax Biolabs

    DMTK

    DermTech

    Frequently Asked Questions

    What is the current stock price of bioAffinity Technologies, Inc. (BIAF)?

    bioAffinity Technologies, Inc. (BIAF) most recently closed at 0.39 USD, a -2.51% move versus the previous session.

    What is the market cap of bioAffinity Technologies, Inc. (BIAF)?

    bioAffinity Technologies, Inc. currently has a market capitalization of 7.62M USD on BioPharmSignal.

    What does bioAffinity Technologies, Inc. do?

    Noninvasive Lung Diagnostics bioAffinity Technologies develops noninvasive tests for the early detection and characterization of lung disease. Its approach uses flow-cytometry and artificial-intelligence analysis of cells collected from sputum samples. CyPath Lung CyPath Lung is a laboratory-developed test intended to help assess patients at elevated risk...

    On which exchange is BIAF stock listed?

    bioAffinity Technologies, Inc. (BIAF) is associated with NASDAQ, United States, MedTech.

    What is Noninvasive?

    Noninvasive Lung Diagnostics bioAffinity Technologies develops noninvasive tests for the early detection and characterization of lung disease.

    Which conditions is bioAffinity Technologies, Inc. targeting with Noninvasive?

    bioAffinity Technologies, Inc. is associated with cancer therapeutics based on its company overview and current catalyst commentary.

    What is Lung?

    Noninvasive Lung Diagnostics bioAffinity Technologies develops noninvasive tests for the early detection and characterization of lung disease.

    What is Diagnostics?

    Noninvasive Lung Diagnostics bioAffinity Technologies develops noninvasive tests for the early detection and characterization of lung disease.